Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:activeIngredient |
gptkb:olanzapine
gptkb:samidorphan |
| gptkbp:approvalYear |
2021
|
| gptkbp:approvedBy |
gptkb:U.S._Food_and_Drug_Administration
|
| gptkbp:ATCCode |
N05AH08
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lybalvi
|
| gptkbp:indication |
gptkb:bipolar_I_disorder
schizophrenia |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alkermes
|
| gptkbp:mechanismOfAction |
opioid
antipsychotic medication |
| gptkbp:reducesSideEffect |
olanzapine-induced weight gain
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:bfsParent |
gptkb:Alkermes
|
| gptkbp:bfsLayer |
7
|